Aroti Hegde, MD
Nephrology · Mc Lean, VANPI 1033164785
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Nuwellis, Inc. accounts for 91.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $13,392 and has fallen 97.8% since, to $292 in 2025. Among nephrology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $292.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nuwellis, Inc.$20K
- Amgen$268
- AstraZeneca$184
- Akebia Therapeutics Inc$183
- Bayer$182
- Vifor Pharma, Inc.$138
- plus $819 from 13 others
What the payments were for
- Speaking & faculty fees$8,32038%
- Travel & lodging$4,60021%
- Food & beverage$8,62840%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nuwellis, Inc. | 7 | $19,876 |
| Amgen | 11 | $268 |
| AstraZeneca | 8 | $184 |
| Akebia Therapeutics Inc | 8 | $183 |
| Bayer | 7 | $182 |
| Vifor Pharma, Inc. | 5 | $138 |
| Fresenius USA Marketing, Inc. | 5 | $117 |
| AbbVie | 1 | $114 |
| Calliditas Therapeutics US Inc. | 2 | $99 |
| Mallinckrodt Enterprises LLC | 4 | $98 |
| Novartis | 3 | $80 |
| Aurinia Pharma U.S., Inc. | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Lilly USA, LLC | 2 | $44 |
| Travere Therapeutics, Inc. | 1 | $38 |
| OPKO Pharmaceuticals, LLC | 1 | $34 |
| Ardelyx, Inc. | 1 | $33 |
| Novo Nordisk | 1 | $27 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUADEX SMARTFLOW CONSOLE$19,720
- Aquadex$125
- QULIPTA$114
How this compares
$21,651 in reported general payments places this provider in the 90th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 200 | $157,373 |
| FarxigaDapagliflozin Propanediol | 181 | $132,163 |
| VelphoroSucroferric Oxyhydroxide | 32 | $114,786 |
| VeltassaPatiromer Calcium Sorbitex | 33 | $42,259 |
| KerendiaFinerenone | 40 | $33,867 |
| EliquisApixaban | 42 | $29,736 |
| LokelmaSodium Zirconium Cyclosilicate | 41 | $28,691 |
| JanuviaSitagliptin Phosphate | 26 | $23,394 |
| EntrestoSacubitril/Valsartan | 25 | $19,951 |
| OzempicSemaglutide | 17 | $19,415 |
| Sevelamer Carbonate | 67 | $16,470 |
| Cinacalcet Hcl | 17 | $10,591 |
| ProsolParenteral Amino Acid 20% No.1 | 51 | $9,018 |
| DapagliflozinDapagliflozin Propanediol | 14 | $6,125 |
| Calcitriol | 144 | $2,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $184 | $160,854222 claims |
| Fresenius USA Marketing, Inc.Velphoro | $117 | $114,78632 claims |
| BayerKerendia | $182 | $33,86740 claims |
| NovartisEntresto | $80 | $19,95125 claims |
| Novo NordiskOzempic | $27 | $19,41517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 298 nephrology providers in Virginia.
Other nephrology in Mc Lean
- Mahesh KrishnanMc Lean$115K
- Ramon MendezWoodbridge$791K
- Reza ZonoziFairfax$262K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
- Gaurav GuptaRichmond$168K
- Csaba KovesdySalem$152K
- Ramin TolouianNorfolk$115K
- Mitchell RosnerCharlottesville$105K
- Neeraja TandraReston$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.